the prevalence round will inevitably grow and present them-
selves in the incidence screening rounds.
In this study at baseline 11 of 17 patients (65%) with
lung cancer could be offered surgical treatment, and a high
proportion 8 of 11(72%) was performed as minimal invasive
surgery (VATS lobectomy), illustrating that early detection
of lung cancer implies more minimal invasive treatment
The randomized study design employed in this and
other current trials will, hopefully, in the coming years,
provide information on the efﬁcacy, beneﬁts and hazards of
lung cancer screening. Such knowledge is essential for bal-
anced and nonbiased recommendations for its eventual im-
plementation in health practice.
1. Mulshine JL, Sullivan DC. Lung cancer screening. N Engl J Med
2. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer
Action Project: overall design and ﬁndings from baseline screening.
Lancet 1999;354:99 –105.
3. Henschke CI, Yankelevitz DF, Libby DM, et al; The International Early
Lung Cancer Action Program Investigators. Survival of patients with
Stage I Lung Cancer Detected on CT screening. N Engl J Med 2006;
4. McMahon PM, Christiani DC. Computed tomography screening for lung
cancer. Results of randomized trials are needed before recommending its
adoption. BMJ 2007;334:271.
5. Black WC, Baron JA. CT screening for lung cancer. Spiraling into
confusion? JAMA 2007;297:995–996.
6. Welch G, Woloshin S, Schwartz LM, et al. Overstating the evidence for
lung cancer screening: the International Early Lung Cancer Action
Program (I-ELCAP) Study. Arch Intern Med 2007;167:2289 –2295.
7. Reich JM. A critical appraisal of overdiagnosis: estimates of its magni-
tude and implications for lung cancer screening. Thorax 2008;63:377–
8. Bach PB, Jett JR, Pastorino U, et al. Computed tomography screening
and lung cancer outcomes. JAMA 2007;297:953–961.
9. Gohagan J, Marcus P, Fagerstrom R, et al. Baseline ﬁndings of a
randomized feasibility trial of lung cancer screening with spiral CT scan
vs chest radiograph. Chest 2004;126:114 –121.
10. The NLST website. Available at: http://www.cancer.gov/nlst. Accessed
January 6, 2009.
11. van Klaveren RJ, Habbema JDF, Pedersen JH, de Koning HJ, Oudkerk
M, Hoogsteden HC. Lung cancer screening by low-dose spiral computed
tomography. Eur Respir J 2001;18:857– 866.
12. van Iersel CA, de Koning HJ, Draisma G, et al. Risk based selection
from the general population in a screening trial: selection criteria,
recruitment and power for the Dutch-Belgian randomised lung cancer
multi-slice CT screening trial (NELSON). Int J Cancer 2006;120:868 –
13. Mascalchi M, Belli G, Zappa M, et al. Risk-beneﬁt analysis of X-ray
exposure associated with lung cancer screening in the Italung-CT trial.
AJR Am J Roentgenol 2006;187:421– 429.
14. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol
of the NELSON randomised lung cancer screening trial. Lung Cancer
15. Fagerstro¨m KO. Towards better diagnoses and more individual treat-
ment of tobacco dependence. Br J Addict 1991;86:543–547.
16. Brodersen J. Measuring psychosocial consequences of false-positive
screening results - breast cancer as an example, Department of General
Practice, Institute of Public Health, Faculty of Health Sciences, University
of Copenhagen: Månedsskrift for Praktisk Lægegerning, Copenhagen.
ISBN: 87-88638-36-7, 2006. Available at: http://cms.ku.dk/sund-sites/
publikationsdetalje/?id⫽1109837. Accessed January 6, 2009.
17. Brodersen J, Thorsen H. Consequences of Screening in Breast Cancer
(COS-BC): development of a questionnaire. Scand J Prim Health Care
18. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for
lung function tests. Eur Respir J 2005;26:948 –968.
19. Thunnissen FB, Kerr KM, Brambilla E, et al. EU-US pathology panel
for uniform diagnosis in randomised controlled trials for CT screening of
lung cancer. Eur Resp J 2006;28:1186–1189.
20. Travis WD, Brambilla E, Muller-Hermelink HK, et al. (Eds.) World
Health Organization Classiﬁcation of Tumors. Pathology and Genetics
of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC press;
21. Libby DM, Wu N, Lee IJ, et al. CT screening for lung cancer: the value
of short term follow-up. Chest 2006;129:1039–1042.
22. Henschke CI, Yankelevitz DF, Naidich DP, et al. CT screening for lung
cancer; suspiciousness of nodules according to size on base line scans.
Radiology 2004;231:164 –168.
23. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer:
ﬁve-year prospective experience. Radiology 2005;235:259 –265.
24. Lidell RM, Hartman TE, Swensen SJ, et al. Five year lung cancer
screening experience. CT appearance, growth rate, location and histo-
logical features of 61 lung cancer cases. Radiology 2007;242:555–562.
25. Veronesi G, Bellomi M, Mulshine JL, et al. Lung cancer screening with
low dose computed tomography: a non-invasive diagnostic protocol for
baseline lung nodules. Lung Cancer 2008;61:340–349.
26. Shaham D, Breuer R, Copel L, et al. Computed tomography screening
for lung cancer: applicability of an international protocol in a single-
institution environment. Clin Lung Cancer 2006;7:262–267.
27. Diederich S, Wormanns D, Thomas M, et al. Screening for early lung
cancer with low-dose spiral CT: prevalence in 817 asymptomatic smok-
ers. Radiology 2002;222:773–781.
28. Xu DM, van Klaveren RJ, de Bock GH, et al. Role of baseline density
and changes in density and nodule features in the discrimination between
benign and malignant solid indeterminate pulmonary nodules. Eur
J Radiol 2008, [Epub ahead of print]. doi: 10.1016/j.ejrad.2008.02.022.
29. Jennings SG, Winer-Muram HT, Tann M, Ying J, Dowdeswell I.
Distribution of stage I lung cancer growth rates determined with serial
volumetric CT measurements. Radiology 2006;241:554 –562.
30. Thunnisen FB, Schuurbiers OC, den Bakker MA. A critical appraisal of
prognostic and predictive factors for common lung cancers. Histopa-
thology 2006;48:779 –786.
31. Ikeda NI, Hayashi A, Miura Y, et al. Present strategy of lung cancer
screening and surgical management. Ann Thor Cardiovasc Surg 2005;
32. Ohtsuka T, Watanabe K, Kaji M, et al. A clinicopathological study of
resected pulmonary nodules with focal pure ground-glass opacity. Eur
J Cardiothor Surg 2006;30:160–163.
33. Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with
pulmonary nodules: when is it lung cancer? ACCP evidence-based
clinical practice guidelines (2nd edition). Chest 2007;132:108 –130.
Pedersen et al. Journal of Thoracic Oncology • Volume 4, Number 5, May 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer614